Articles

December 29, 2010 - Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific...

In the world of endovascular devices, the rule is no longer one size fits all. The recent increase in the variety of stents for percutaneous coronary intervention (PCI) offers the physician of a...

There is no consensus about whether atherosclerotic renal artery stenosis should be stented or treated medically. There are strong opinions on both sides and clinical data up to now is heavily...

In recent years, many medical device companies saw the underserved lower extremity as an opportunity to enter the market for peripheral artery disease (PAD) treatments. For this reason, device...

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...

Editor’s note: Dr. Samady is an associate professor of medicine, division of cardiology,
Emory University School of Medicine, Atlanta. He wrote the following commentary on his...

Fractional flow reserve (FFR) is starting to change cardiologists’ minds about how to treat patients since the release of two-year results from the FAME (FFR vs. Angiography in Multivessel...

In recent years, the U.S. cardiac device market has focused on dynamics in the drug-eluting stent (DES) segment – including events ranging from the 2006 BASKET-LATE trial that caused a tremendous...

Standard drug-eluting stent technology seemed to have taken a backseat at this year’s TCT as cardiologists look forward to the next-generation DES using bioresorbable polymer coatings and totally...

September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent...